Dr Thomas Seck, who is the vice president of Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals, discusses the EMPERIAL trials, which aim to expand the use of empagliflozin for heart failure.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
